These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 27042079)

  • 1. Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations.
    Prosperini L; Pontecorvo S
    Ther Clin Risk Manag; 2016; 12():339-50. PubMed ID: 27042079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dimethyl fumarate for multiple sclerosis.
    Xu Z; Zhang F; Sun F; Gu K; Dong S; He D
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD011076. PubMed ID: 25900414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S; Kumar J; Arndorfer S; Zhu X; Zivkovic M; Tencer T
    CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
    Wray S; Then Bergh F; Wundes A; Arnold DL; Drulovic J; Jasinska E; Bowen JD; Negroski D; Naismith RT; Hunter SF; Gudesblatt M; Chen H; Lyons J; Shankar SL; Kapadia S; Mendoza JP; Singer BA
    Adv Ther; 2022 Apr; 39(4):1810-1831. PubMed ID: 35211872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
    Gold R; Arnold DL; Bar-Or A; Fox RJ; Kappos L; Mokliatchouk O; Jiang X; Lyons J; Kapadia S; Miller C
    Mult Scler; 2022 Apr; 28(5):801-816. PubMed ID: 34465252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).
    Gold R; Giovannoni G; Phillips JT; Fox RJ; Zhang A; Meltzer L; Kurukulasuriya NC
    Mult Scler; 2015 Jan; 21(1):57-66. PubMed ID: 24990854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
    Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab for people with multiple sclerosis.
    Filippini G; Kruja J; Del Giovane C
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013874. PubMed ID: 34748215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
    Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
    Naismith RT; Wundes A; Ziemssen T; Jasinska E; Freedman MS; Lembo AJ; Selmaj K; Bidollari I; Chen H; Hanna J; Leigh-Pemberton R; Lopez-Bresnahan M; Lyons J; Miller C; Rezendes D; Wolinsky JS;
    CNS Drugs; 2020 Feb; 34(2):185-196. PubMed ID: 31953790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM.
    Fox RJ; Gold R; Phillips JT; Okwuokenye M; Zhang A; Marantz JL
    Neurol Ther; 2017 Dec; 6(2):175-187. PubMed ID: 28770420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events.
    Calabrese M; Pitteri M; Farina G; Bajrami A; Castellaro M; Magliozzi R; Monaco S
    J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1073-1078. PubMed ID: 28844068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
    Gold R; Giovannoni G; Phillips JT; Fox RJ; Zhang A; Marantz JL
    Neurol Ther; 2016 Jun; 5(1):45-57. PubMed ID: 26932146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.
    Phillips JT; Selmaj K; Gold R; Fox RJ; Havrdova E; Giovannoni G; Abourjaily H; Pace A; Novas M; Hotermans C; Viglietta V; Meltzer L
    Int J MS Care; 2015; 17(5):236-43. PubMed ID: 26472945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate.
    Jožef M; Locatelli I; Brecl Jakob G; Rot U; Kos M
    Mult Scler Relat Disord; 2023 Apr; 72():104615. PubMed ID: 36933300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
    Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies.
    Amezcua L; Mao-Draayer Y; Vargas WS; Farber R; Schaefer S; Branco F; England SM; Belviso N; Lewin JB; Mendoza JP; Shankar SL;
    Neurol Ther; 2023 Jun; 12(3):883-897. PubMed ID: 37061656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence.
    Narapureddy B; Dubey D
    Patient Prefer Adherence; 2019; 13():1655-1666. PubMed ID: 31631980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.